Processing

Please wait...

Settings

Settings

Goto Application

1. WO2006102079 - N- [3- (1-AMIN0-5, 6, 7, 8-TETRAHYDRO-2 , 4, 4B-TRIAZAFLUOREN-9-YL)-PHENYL] BENZAMIDES AS TYROSINE/THREONINE KINASE INHIBITORS, IN PARTICULAR B-RAF KINASE

Publication Number WO/2006/102079
Publication Date 28.09.2006
International Application No. PCT/US2006/009713
International Filing Date 17.03.2006
IPC
C07D 471/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
12in which the condensed system contains three hetero rings
14Ortho-condensed systems
C07D 487/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61K 31/519 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 9/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
10for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
06Antimigraine agents
CPC
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
04Centrally acting analgesics, e.g. opioids
A61P 25/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
06Antimigraine agents
A61P 27/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27Drugs for disorders of the senses
02Ophthalmic agents
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • NOVARTIS AG [CH]/[CH] (AllExceptUS)
  • NOVARTIS PHARMA GmbH [AT]/[AT] (AT)
  • PEREZ, Lawrence, Blas [US]/[US] (UsOnly)
  • SHENG, Tao [CA]/[US] (UsOnly)
Inventors
  • PEREZ, Lawrence, Blas
  • SHENG, Tao
Agents
  • KONZAK, Kristin, E.
Priority Data
60/662,88917.03.2005US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) N- [3- (1-AMIN0-5, 6, 7, 8-TETRAHYDRO-2 , 4, 4B-TRIAZAFLUOREN-9-YL)-PHENYL] BENZAMIDES AS TYROSINE/THREONINE KINASE INHIBITORS, IN PARTICULAR B-RAF KINASE
(FR) N- [3- (1-AMIN0-5, 6, 7, 8-TETRAHYDRO-2, 4, 4B-TRIAZAFLUOREN-9-YLE)-PHENYL] BENZAMIDES UTILISES EN TANT QU'INHIBITEURS DE TYROSINE/THREONINE KINASE, EN PARTICULIER LA B-RAF KINASE
Abstract
(EN)
The present invention relates to compounds that are useful to inhibit, regulate and/or modulate tyrosine and serine/threonine kinase and kinase-like proteins, such as RAF kinase, a serine/threonine kinase that functions in the MAP kinase signaling pathway. The application is also concerned with compositions which contain these compounds, and methods of using them to treat tyrosine and serine/threonine kinase and kinase-like dependent diseases, such as angiogenesis, cancer and cardiac hypertrophy, and with other subject matter.
(FR)
L'invention concerne des composés utilisés pour inhiber, réguler et/ou moduler la tyrosine et la sérine/thréonine kinase et des protéines de type kinase, telles que la RAF kinase, une sérine/thréonine kinase qui fonctionne dans le passage de signalisation de la MAP kinase. L'application concerne également des compositions contenant lesdits composés, et des procédés d'utilisation des compositions, permettant de traiter les maladies engendrées par la tyrosine et la sérine/ thréonine kinase et du type de kinase, telles que l'angiogenèse, le cancer, l'hypertrophie cardiaque, et dans d'autres applications.
Latest bibliographic data on file with the International Bureau